epocrates
Biogen discontinues Alzheimer disease drug Aduhelm
Biogen announced that it will end its post-approval study of Alzheimer’s disease (AD) treatment Aduhelm and return the licensing rights to Neurimmune, from which it had licensed the drug in 2007. The company explained that it was concerned that by the time the drug received standard approval, new treatments would be on the market. Biogen had discontinued efforts to commercialize the drug in 2022 after a decision was made by Medicare to limit coverage of the drug. The company will focus its efforts on the launch of Leqembi and on two new experimental drugs that target tau, a protein associated with AD.
Sources:
Leio, L et al. (2024, January 31). Reuters. Biogen drops Alzheimer’s drug Aduhelm, ending a 17-year chapter. https://www.reuters.com/business/healthcare-pharmaceuticals/biogen-discontinue-development-older-alzheimers-drug-aduhelm-2024-01-31/
(2024, January 31). Biogen. Biogen to realign resources for Alzheimer’s disease franchise. [News release]. https://investors.biogen.com/news-releases/news-release-details/biogen-realign-resources-alzheimers-disease-franchise